How Beta-Endorphin in the Brain Suppresses Male Sexual Function

Beta-endorphin injected into the medial preoptic area dose-dependently impaired male rat sexual behavior, more potently than other opioid peptides, and was blocked by naloxone.

van Furth, W R et al.·Behavioral neuroscience·1995·Moderate EvidenceAnimal StudyAnimal Study
RPEP-00345Animal StudyModerate Evidence1995RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Beta-endorphin in the MPOA dose-dependently impaired male rat sexual behavior, prevented by naloxone, while other opioid peptides were less effective at equivalent doses.

Key Numbers

How They Did This

Sexually experienced male rats received local MPOA infusions of beta-endorphin, alpha-endorphin, dynorphin A, or met-enkephalin. Sexual behavior parameters were measured during standard mating tests. Naloxone was tested as a blocker.

Why This Research Matters

Opioid drugs commonly cause sexual dysfunction. This study identifies the specific brain region and the specific opioid peptide (beta-endorphin) most responsible for suppressing male sexual function.

The Bigger Picture

Sexual dysfunction is one of the most common and distressing side effects of opioid medications. This study pinpoints the specific brain region (MPOA) and specific peptide (beta-endorphin) responsible, which could guide development of opioid drugs that spare sexual function.

What This Study Doesn't Tell Us

Animal study in rats with direct brain injection. Sexual behavior in rats does not directly model human sexual function. Only male rats were studied.

Questions This Raises

  • ?Can opioid drugs be designed that avoid suppressing MPOA function while maintaining pain relief?
  • ?Does chronic opioid use cause lasting changes to MPOA beta-endorphin sensitivity?

Trust & Context

Key Stat:
Beta-endorphin most potent Among 4 opioid peptides tested, beta-endorphin most strongly suppressed sexual behavior in the MPOA
Evidence Grade:
Moderate — controlled animal study with dose-response curves, naloxone reversal, and comparison across multiple opioid peptides.
Study Age:
Published in 1995. The role of the MPOA in opioid-induced sexual dysfunction has been confirmed by subsequent research and remains clinically relevant.
Original Title:
Opioids and sexual behavior of male rats: involvement of the medial preoptic area.
Published In:
Behavioral neuroscience, 109(1), 123-34 (1995)
Database ID:
RPEP-00345

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Why do opioid medications affect sexual function?

Opioid peptides, especially beta-endorphin, suppress the brain region (medial preoptic area) that controls sexual motivation and performance. Opioid drugs activate the same pathway.

Can this side effect be treated?

Naloxone (an opioid blocker) reversed the effect in this study. Clinically, opioid-induced sexual dysfunction is sometimes managed with dose adjustment, opioid rotation, or hormone supplementation.

Read More on RethinkPeptides

Cite This Study

RPEP-00345·https://rethinkpeptides.com/research/RPEP-00345

APA

van Furth, W R; van Emst, M G; van Ree, J M. (1995). Opioids and sexual behavior of male rats: involvement of the medial preoptic area.. Behavioral neuroscience, 109(1), 123-34.

MLA

van Furth, W R, et al. "Opioids and sexual behavior of male rats: involvement of the medial preoptic area.." Behavioral neuroscience, 1995.

RethinkPeptides

RethinkPeptides Research Database. "Opioids and sexual behavior of male rats: involvement of the..." RPEP-00345. Retrieved from https://rethinkpeptides.com/research/van-1995-opioids-and-sexual-behavior

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.